...
首页> 外文期刊>Therapeutic Drug Monitoring >Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.
【24h】

Effect of route of administration on the pharmacokinetic behavior of enantiomers of nefopam and desmethylnefopam.

机译:给药途径对奈福opa和去甲基奈福opa对映异构体药代动力学行为的影响。

获取原文
获取原文并翻译 | 示例

摘要

Nefopam hydrochloride is a non-narcotic analgesic used parenterally and orally as a racemic mixture for the relief of postoperative pain. However, no information is presently available on the oral kinetics of (+) and (-) nefopam in humans. Also, nefopam is metabolized by N-demethylation but it is not known whether the desmethylnefopam enantiomers (DES1 and DES2) are present in plasma following intravenous (I.V.) or oral administration of parent drug. To address these issues, 24 healthy white male subjects received two treatments using a double-blind, placebo-controlled crossover design: oral administration of 20 mg nefopam hydrochloride solution or a placebo solution on a sugar cube, simultaneously with a continuous infusion of 20 mg nefopam hydrochloride or placebo infusion. A chiral assay using LC-MS was developed for the simultaneous determination of both enantiomers of the parent drug and its metabolite in plasma and urine. Following I.V. administration, the kinetics of (+) and (-) nefopam could befitted to a bi-exponential equation but exhibited no stereoselectivity. Both enantiomers had large clearances (53.7 and 57.5 L/hr) and volumes of distribution (390 and 381 L) and half-lives around 5 hours. Following oral administration, (+) and (-) nefopam were rapidly absorbed with bioavailabilities of 44% and 42%, respectively, probably due to a first-pass effect. After I.V. administration, the enantiomers of desmethylnefopam exhibited lower concentrations and longer half-lives (20.0 h for DES1 and 25.3 h for DES2) relative to nefopam enantiomers. Following oral administration, desmethylnefopam enantiomers' plasma concentrations peaked earlier and higher than after I.V. administration (P < 0.05). Following I.V. and oral administration, desmethylnefopam enantiomers showed stereoselectivity in AUC and Cmax values. Urinary excretion of parent and metabolite enantiomers was less than 5% of dose. This study shows that desmethylnefopam enantiomers can contribute to the analgesic effect of racemic nefopam only when it is administered orally.
机译:盐酸奈非帕姆是一种非麻醉性镇痛药,经肠胃外和口服用作消旋混合物,可减轻术后疼痛。但是,目前尚无有关人类中(+)和(-)nefopam口服动力学的信息。另外,奈福opa通过N-去甲基化代谢,但是尚不清楚在静脉内(IV)或口服母体药物后血浆中是否存在去甲基奈福opa对映异构体(DES1和DES2)。为了解决这些问题,24名健康的白人男性受试者接受了使用双盲,安慰剂对照的交叉设计的两种治疗:在糖方糖上口服20 mg盐酸奈非帕姆溶液或安慰剂溶液,同时连续输注20 mg盐酸奈福opa或安慰剂输注。开发了一种使用LC-MS的手性测定法,用于同时测定母体药物及其代谢物在血浆和尿液中的对映异构体。继IV给药时,(+)和(-)nefopam的动力学可以拟合为双指数方程,但没有立体选择性。两种对映异构体均具有较大的清除率(53.7和57.5 L / hr)和分布体积(390和381 L),并且半衰期约为5小时。口服后,(+)和(-)奈福ne迅速吸收,生物利用度分别为44%和42%,这可能是由于首过效应所致。在IV之后给药后,相对于奈福。对映体,去甲基奈福opa的对映体显示出较低的浓度和较长的半衰期(DES1为20.0 h,DES2为25.3 h)。口服后,去甲基奈福ne对映异构体的血浆浓度比静脉内注射更早且更高。 (P <0.05)。继IV口服时,去甲基去甲烯对映体的AUC和Cmax值具有立体选择性。母体和代谢物对映体的尿排泄量小于剂量的5%。这项研究表明,去甲基奈福opa对映异构体仅在口服时才可以起到消旋奈福opa的止痛作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号